A Randomized Double Blind Placebo Controlled Parallel Group Study Of The Efficacy And Safety Of Pregabalin (Bid) In Subjects With Post-traumatic Peripheral Neuropathic Pain
Phase of Trial: Phase III
Latest Information Update: 01 Dec 2018
At a glance
- Drugs Pregabalin (Primary)
- Indications Neuropathic pain
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 25 Nov 2015 According to Pfizer media release, primary endpoint (Change from baseline to Week 15 (endpoint) mean pain score. [ Time Frame: Baseline, Week 15]) has not been met.
- 18 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.